[Clinical use and evolution of circulating biomarkers in the era of personalized oncology: From protein markers to bioclinical scores]

Abstract

In oncology, the identification of targets that correlate with a type of cancer has led to a profound change in the notion of "tumor markers". Technological advances, in particular the development of high-throughput sequencing, have led to the emergence of a new generation of molecular biomarkers for tumors. Despite their limited utility for screening and diagnosis, conventional tumor markers remain interesting for evaluation of prognoses, the choice and optimization of treatments, as well as for monitoring the effectiveness of those treatments. In this article, we revisit the conventional serum markers that are enjoying a 'come back' thanks to the development of high-performance scores based on biological, cytological, clinical, or radiological criteria.

Keywords: Biomarkers; Biomarqueurs; Biopsie liquide; Clinicobiological scores; Combinaison; Combination; Liquid biopsy; Marqueurs tumoraux; Scores clinicobiologiques; Tumoral markers.